Proinflammatory Protein CARD9 Is Essential for Infiltration of Monocytic Fibroblast Precursors and Cardiac Fibrosis Caused by Angiotensin II Infusion

Jingyuan Ren1,2, Min Yang1,2, Guanming Qi1,2, Jiao Zheng1,2, Lixin Jia1,2, Jizhong Cheng1,2, Cui Tian3, Huihua Li3, Xin Lin1,2 and Jie Du1,2

BACKGROUND
Angiotensin II (Ang II)–induced cardiac remodeling with the underlying mechanisms involving inflammation and fibrosis has been well documented. Cytosolic adaptor caspase recruitment domain 9 (CARD9) has been implicated in the innate immune response. We aimed to examine the role of CARD9 in inflammation and cardiac fibrosis induced by Ang II.

METHODS
Two-month-old CARD9-deficient (CARD9−/−) and wild-type (WT) male mice were infused with Ang II (1,500 ng/kg/min) or saline for 7 days. Heart sections were stained with hematoxylin and eosin and Masson trichrome and examined by immunohistochemistry; and activity and protein levels were measured in macrophages obtained from mice.

RESULTS
WT mice with Ang II infusion showed a marked increase in CARD9+ macrophages in the heart, but CARD9−/− mice showed significantly suppressed macrophage infiltration and expression of proinflammatory cytokines, including interleukin-1β (IL-1β) and connective tissue growth factor (CTGF). Importantly, Ang II–induced cardiac fibrosis (extracellular matrix and collagen I deposition) was diminished in CARD9−/− hearts, as was the expression of transforming growth factor-β (TGF-β) and level of myofibroblasts positive for α-smooth muscle actin (α-SMA). Furthermore, Ang II activation of nuclear factor-κB (NF-κB), JNK and p38 mitogen-activated protein kinases (MAPKs) in WT macrophages was reduced in CARD9−/− macrophages.

CONCLUSION
CARD9 plays an important role in regulating cardiac inflammation and fibrosis in response to elevated Ang II.

Keywords: blood pressure; CARD9; cardiac fibrosis; hypertension; inflammation; myofibroblast; NF-κB

The role of inflammation in fibrosis has been shown by recent studies describing an important role for blood-borne, monocytic fibroblast precursors that express CD34 and CD45 in Ang II–induced or other pathological interstitial cardiac fibrosis.5 Ang II infusion resulted in the appearance of bone marrow-derived CD34+/CD45+ fibroblast precursor cells that expressed collagen type I and the cardiac fibroblast marker DDR2, and structural fibroblasts were negative for CD34/CD45.6 Moreover, knockout (KO) of monocyte chemoattractant protein 1 prevented Ang II–induced infiltration of CD34+/CD45+ fibroblast precursor cells and cardiac fibrosis.

Growing evidence indicates that Ang II influences all stages of the inflammatory response involved in inflammatory gene expression. Via its AT1 receptor, Ang II activates NADPH oxidase and produces reactive oxygen species, thus leading to activation of the transcriptional factors Ets-1, early growth response 1, and nuclear factor-κB (NF-κB). We previously showed that in vascular smooth muscle cells, Ang II activates NF-κB via an IKK- and a mitogen-activated protein kinase (MAPK)-dependent mechanism.7–9 However, how Ang II activates NF-κB in inflammatory cells remains unknown.

1Beijing Anzhen Hospital Affiliated to the Capital Medical University, Beijing, China; 2The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Capital Medical University, Ministry of Education, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China; 3Department of Pathology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. Correspondence: Jie Du (jdu@bcm.edu)

Received 17 September 2010; first decision 2 November 2010; accepted 16 February 2011.

© 2011 American Journal of Hypertension, Ltd.

AMERICAN JOURNAL OF HYPERTENSION | VOLUME 24 NUMBER 6 | 701-707 | JUNE 2011
The caspase-recruitment domain (CARD) is a protein-binding module that mediates the assembly of CARD-containing proteins. Cytosolic adaptor caspase recruitment domain 9 (CARD9) has received much attention. It consists of an amino-terminal CARD and a carboxyterminal coiled-coil domain and is closely related to the well-characterized CARD-containing adaptor CARMA1 (also called CARD11 and Bimp3). CARD9 is expressed in various tissues, including spleen, liver, placenta, lung, leukocytes, with highest expression in macrophages and dendritic cells. Several studies of CARD9-deficient mice demonstrated that CARD9 is involved in inducing cytokine activity and in protection against fungal and bacterial infection. CARD9 has disparate functions in these two pathways, linking tyrosine kinases to activation of the transcription factor NF-κB and toll-like receptors to MAPKs, including p38 and JNK. Although such data suggest that CARD9 plays a central role in the innate immune response, no studies have examined the effects of CARD9 on inflammation and cardiac fibrosis.

Given the role of CARD9 in inflammation, we sought to determine the role of CARD9 signaling in Ang II-induced inflammation and cardiac fibrosis. We used a mouse model with KO of the CARD9 gene and Ang II infusion. Cardiac fibrosis and inflammatory response induced by Ang II infusion was markedly inhibited in CARD9−/− mice.

METHODS

Animal model. CARD9-KO (CARD9−/−) mice were kindly supplied by Dr Lin (Department of Molecular and Cellular Oncology, University of Texas, Houston, TX). Two-month-old CARD9−/− and littermate wild-type (WT) male mice of the same C57BL/6 background were used. Mice were implanted with osmotic pumps (Alzet MODEL 1007D; DURECT, Cupertino, CA) filled with Ang II and infused at 1,500 ng/kg/min in Ringer’s solution (0.01 mmol/l Tris (pH 7.5), 150 mmol/l NaCl, 1 mmol/l EDTA, 1 mmol/l EGTA, 1% Triton X-100, 2.5 mmol/l sodium pyrophosphate, 1 mmol/l β-glycerophosphate, 1 mmol/l Na3VO4, 4 μg/ml aprotinin, 4 μg/ml leupeptin, 4 μg/ml pepstatin, and 1 mmol/l PMSF). Western blot analysis was performed as described. In total, 50 μg cell protein was loaded on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels, transferred to nitrocellulose membrane, and probed with the primary antibodies against CARD9, β-actin (Santa Cruz Biotechnology), phospho-p65 (Ser536), p65, phospho-JNK1/2 (Thr183/Tyr185), JNK1/2, phospho-p38 (Thr180/Tyr182), and p38 (all Cell Signaling Technology, Danvers, MA). After being washed extensively, the membranes were then incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The signals were visualized by use of an enhanced chemiluminescence kit (Amersham, Piscataway, NJ). The levels of signaling proteins were normalized to that of β-actin.

Histology and immunohistochemistry. Animals were killed 7 days after Ang II or saline infusion. Hearts were isolated and fixed in 4% paraformaldehyde solution. The samples were cut into 5-μm sections and stained with hematoxylin and eosin by standard procedures. To measure fibrotic areas, sectioned hearts were stained with Masson trichrome. The interstitial fibrotic areas were calculated as the ratio of total area of interstitial fibrosis to total area of the section. Immunohistochemical analysis involved antibodies against CARD9 (1:200 dilution), Mac-2 (1:400 dilution), interleukin-1β (IL-1β) (1:200 dilution), transforming growth factor-β (TGF-β) (1:300 dilution; all Santa Cruz Biotechnology, Santa Cruz, CA); and collagen I (1:1,000 dilution). Anti-F4/80 (1:100 dilution; Abcam, Cambridge, MA), which recognizes the mouse F4/80 antigen, a 160 kDa glycoprotein expressed a wide range of mature tissue macrophages including Kupffer cells, Langerhans cells, microglia, macrophages located in the gut lamina propria, peritoneal cavity, lung, thymus, bone marrow stroma, and macrophages in the red pulp of the spleen. The macrophages we used in in vitro study were from peritoneal cavity. α-Smooth muscle actin (α-SMA) (1:200 dilution) described previously. Images were viewed and captured by use of a Nikon Labophot 2 microscope equipped with a Sony CCD-Iris/RGB color video camera attached to a computerized imaging system and analyzed by ImagePro Plus 3.0 (ECLIPSE80i/90i; Nikon, Tokyo, Japan).

Cell culture. Isolation of mouse peritoneal macrophages was as described. Briefly, 8–10-week-old mice were injected with 2 ml of 4% thioglycollate medium. Then, 4 days later, mice were killed and the peritoneal cavity was flushed with 5-ml cold phosphate-buffered solution. The macrophages were resuspended with 10% fetal bovine serum and 1:100 penicillin/streptomycin. Nonadherent cells were removed after 4 h, and the medium was replaced with fresh medium.

NF-κB luciferase reporter assay. NF-κB transactivation activity was measured by use of adenovirus infection with NF-κB luciferase reporter (Ad.NF-κB-Luc) as described. Briefly, peritoneal macrophages from WT and CARD9−/− mice were infected with Ad.NF-κB-Luc at a multiplicity of infection of 5 for 24 h before 100 mmol/l Ang II treatment; from each sample, 5 μg total protein underwent luciferase activity assay according to the manufacturer’s protocol (Promega, Madison, WI).

Western blot analysis. Cells were lysed with lysis buffer (20 mmol/l Tris (pH 7.5), 150 mmol/l NaCl, 1 mmol/l EDTA, 1 mmol/l EGTA, 1% Triton X-100, 2.5 mmol/l sodium pyrophosphate, 1 mmol/l β-glycerophosphate, 1 mmol/l Na3VO4, 4 μg/ml aprotinin, 4 μg/ml leupeptin, 4 μg/ml pepstatin, and 1 mmol/l PMSF). Western blot analysis was performed as described. In total, 50 μg cell protein was loaded on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels, transferred to nitrocellulose membrane, and probed with the primary antibodies against CARD9, β-actin (Santa Cruz Biotechnology), phospho-p65 (Ser536), p65, phospho-JNK1/2 (Thr183/Tyr185), JNK1/2, phospho-p38 (Thr180/Tyr182), and p38 (all Cell Signaling Technology, Danvers, MA). After being washed extensively, the membranes were then incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The signals were visualized by use of an enhanced chemiluminescence kit (Amersham, Piscataway, NJ). The levels of signaling proteins were normalized to that of β-actin.
**Statistical analysis.** Data are expressed as mean ± s.e.m. Statistical analysis involved one-way ANOVA followed by LSD t-test for multiple comparisons within treatment groups. Analysis involved use of SPSS v13.0 (SPSS, Chicago, IL). *P* < 0.05 was considered statistically significant.

**RESULTS**

**Ang II infusion stimulates infiltration of CARD9+ inflammatory cells into mouse hearts**

To investigate the role of CARD9 in the development of Ang II–induced cardiac remodeling, WT mice were infused with Ang II, 1,500 ng/kg/min, for 7 days. The systolic blood pressure, heart weight/body weight (HW/BW) and heart weight/tibia length (HW/TL) ratios were measured (Table 1). Baseline BP, HW/BW, and HW/TL ratios were similar in both WT and KO mice. After Ang II treatment, these parameters tended to be increased in KO mice compared with WT mice, but the difference was not statistically significant. Immunohistochemistry revealed that Ang II infusion significantly increased the number of CARD9+ cells in mouse hearts as compared with the control group (*P* < 0.05; Figure 1a).

CARD9 is known to be highly expressed in macrophages.11 We then examined whether CARD9 is expressed in macrophages from myocardial tissues or from the peritoneal cavity using double immunostaining for F4/80 (for macrophages) and CARD9. CARD9 was expressed in macrophages, and its expression was markedly induced after Ang II infusion (Figure 1b,c).

**CARD9 deficiency inhibits myocardial inflammation induced by Ang II in mouse hearts**

Inflammatory cell infiltrates were markedly increased in WT mice after Ang II infusion as compared with untreated WT mice (Figure 2a). The infiltration of inflammatory cells after Ang II was lower in CARD9−/− mice than in WT mice (*P* < 0.05). Furthermore, immunohistochemical staining of myocardial sections demonstrated the expression of Mac-2 (macrophage marker). IL-1β and CTGF significantly increased in Ang II–treated WT mice as compared with untreated WT mice, with the increased expression significantly lower in CARD9−/− mice than in WT mice after Ang II infusion (Figure 2b–d). The protein expression of Mac-2, IL-1β, and CTGF did not differ between WT and CARD9−/− mice without Ang II treatment (Figure 2b–d). Moreover, the numbers of TUNEL-positive cardiomyocytes were comparable between WT and KO mice following 7 days of Ang II infusion (data not shown).

**CARD9 deficiency attenuates cardiac fibrosis induced by Ang II in mouse hearts**

We then determined the role of CARD9 in the development of cardiac fibrosis. Systolic blood pressure was markedly increased in both WT and CARD9−/− mice after Ang II infusion, with no significant difference between WT and CARD9−/− mice (data not shown). Moreover, heart sections stained with Masson trichrome for measurement of fibrotic areas showed that Ang II infusion significantly increased cardiac fibrotic areas in Ang II–treated WT mice as compared with untreated WT mice (Figure 3a). However, in CARD9−/− mice, the fibrotic areas were significantly smaller than in WT mice with Ang II treatment. WT and CARD9−/− mice did not differ in cardiac fibrotic areas without Ang II treatment. Moreover, immunohistochemistry confirmed that with Ang II treatment, the increased protein levels of collagen I and TGF-β in WT mice were markedly suppressed in CARD−/− mice (Figure 3b,c). With Ang II treatment, the protein expression of α-SMA, a marker of myofibroblasts, was markedly elevated in WT mice but significantly reduced in CARD−/− mice (*P* < 0.01; Figure 3d).

**Effect of CARD9 on the activation of NF-κB and MAPK signaling pathways in mouse peritoneal macrophages**

To determine the mechanisms of the inhibition of cardiac inflammation and fibrosis in CARD9−/− mice after Ang II infusion, we first examined the CARD9 downstream target NF-κB activity in peritoneal macrophages using NF-κB luciferase reporter assay. Ang II treatment dose-dependently increased NF-κB luciferase activity in WT macrophages (Figure 4a), which was significantly suppressed in CARD−/− macrophages.

---

**Table 1 | Body weight, systolic BP, HW/BW and HW/TL ratios**

| Parameters   | WT (n=6) | KO (n=6) | WT + Ang II (n=6) | KO + Ang II (n=6) |
|--------------|----------|----------|-------------------|-------------------|
| BP (mm Hg)  | 97.33 ± 6.03 | 93.33 ± 4.62 | 135 ± 10         | 144 ± 12         |
| HW/BW (mg/g) | 5.03 ± 0.35 | 5.22 ± 0.26 | 5.74 ± 0.81 | 6.00 ± 0.77   |
| HW/TL (mg/mm) | 7.01 ± 0.04 | 6.86 ± 0.37 | 8.12 ± 0.99 | 9.31 ± 1.82  |

Ang II, angiotensin II; BP, blood pressure; BW, body weight; HW, heart weight; KO, knockout; TL, tibia length; WT, wild type.

---

**Figure 1 | Angiotensin II (Ang II) infusion induces cytosolic adaptor caspase recruitment domain 9 (CARD9) expression in macrophages of cardiac tissues.** Wild-type (WT) mice were infused with Ang II at 1,500 ng/kg/min for 7 days, and heart tissues were harvested. (a) Heart sections from saline- and Ang II–treated mice stained with anti-CARD9 antibody (Ab) (left). Bar = 50 μm. F4/80 (macrophages) and CARD9 immunofluorescence staining of (b) cardiac tissues or (c) peritoneal macrophages from both WT and CARD9−/− mice infused with or without Ang II.
We next examined the activation of NF-κB and MAPKs in peritoneal macrophages by Western blot analysis. Without Ang II treatment, levels of NF-κB/p65, p38, and JNK1/2 phosphorylation were lower in CARD9−/− than WT macrophages (Figure 4b). However, Ang II markedly activated NF-κB/p65, p38, and JNK1/2 in WT macrophages as compared with untreated WT cells. Activation of NF-κB/p65, p38, or JNK1/2 was similar in CARD9−/− macrophages before and after Ang II treatment (Figure 4b).

**Figure 2** | Cytosolic adaptor caspase recruitment domain 9 (CARD9) deficiency inhibits angiotensin II (Ang II) infusion–induced proinflammatory cell infiltration and expression of inflammatory cytokines. (a) Heart sections from wild-type (WT) and CARD9−/− mice treated with saline or Ang II at 1,500 ng/kg/min for 7 days were stained with hematoxylin and eosin (HE). (b–d) Heart sections from WT and CARD9−/− mice were detected by immunohistochemistry with antibodies against Mac-2, interleukin-1β (IL-1β), and connective tissue growth factor (CTGF) (top). Bar graph shows quantified areas (bottom). Bar = 50 μm. Data represent mean ± s.e.m. (n = 5). *P < 0.01 vs. WT+Ang II.

**Figure 3** | Cytosolic adaptor caspase recruitment domain 9 (CARD9) knockout prevents angiotensin II (Ang II) infusion–induced cardiac fibrosis. (a) Representative Masson trichrome staining of heart sections from wild-type (WT) and CARD9−/− mice (top). Bar graph shows quantified fibrotic areas on histological sections (bottom). (b–d) Heart sections from WT and CARD9−/− mice were detected by immunohistochemistry with antibodies against collagen I, transforming growth factor-β (TGF-β), and α-smooth muscle actin (α-SMA) (top). Bar graph shows quantified areas (bottom). Bar = 50 μm. Data were represented as the mean ± s.e.m. (n = 5). *P < 0.01 vs. WT+Ang II.
CARD9−/− mice, stimulation of dendritic cells caused a marked decreased numbers of Th17 cells.31–33 Humans with CARD9 decrease in the production of IL-2, -6, and -10, and TNF-α and mechanisms for these effects are not fully understood. 24–28 In the cardiac fibrosis and inflammation, the precise molecular mechanisms associated with reduced activation of the NF-κB/MAPK signaling pathway, expression of proinflammatory cytokines and accumulation of α-SMA+ myofibroblasts with Ang II infusion. Thus, CARD9 is important in hypertensive cardiac remodeling induced by Ang II infusion.

Cardiac fibrosis and inflammation are the major events of Ang II–induced myocardial remodeling. CARD9 is a caspase recruitment–domain–containing signaling protein expressed in various tissues.10,11 It is closely associated with several inflammatory diseases, including tuberculosis, inflammatory bowel disease, tuberculosis, and ankylosing spondylitis.13,29,30 In CARD9−/− mice, stimulation of dendritic cells caused a marked decrease in the production of IL-2, -6, and -10, and TNF-α and decreased numbers of Th17 cells.31–33 Humans with CARD9 mutation show defects in inflammation responses.34 Given the important role of CARD9 in inflammation, we investigated the role of CARD9 in cardiac inflammation and fibrosis after Ang II infusion. We found infiltrated macrophages expressing CARD9 in response to Ang II infusion. The critical role of CARD9 was demonstrated by Ang II–induced macrophage infiltration, and the expression of TGF-β, collagen I, α-SMA, IL-1β, and CTGF was significantly inhibited in CARD9−/− mice with Ang II infusion (Figures 2 and 3).

Myofibroblast formation is controlled by a number of growth factors, cytokines, and mechanical stimuli.35 In the present study, the number of α-SMA+ myofibroblasts in myocardial tissues of CARD9−/− mice was significantly lower than that of WT mice after Ang II infusion (Figure 3). Moreover, the expression of collagen I and TGF-β was markedly decreased in CARD9−/− mice (Figure 3). Therefore, CARD9 deficiency inhibits cardiac fibrosis by inhibiting myofibroblast formation.

Increasing evidence has demonstrated that Ang II, via its type 1 receptor, activates a number of signaling pathways, including reactive oxygen species, MAPKs, receptor- or nonreceptor-associated tyrosine kinases, and transcriptional factors such as NF-κB, Ets-1, and early growth response 1 to regulate cardiac hypertrophy, inflammation, and fibrosis.36 Among these, NF-κB and MAPK signaling pathways play pivotal roles in regulating the inflammatory, immune, and apoptotic responses in mammals.37 Ang II, via AT1R activation, also increases production of aldosterone which is a steroid hormone with mineralocorticoid activity. Beyond its effects on renal sodium reabsorption, aldosterone exerts effects on the kidney, blood vessels, and the heart, and plays an important role in renal and cardiovascular injury, including inflammation, tissue remodeling and fibrosis, has been demonstrated in various animal models of hypertension.38,39 The aldosterone increases tissue angiotensin-converting enzyme activity and upregulates AT1, indicating a vicious forward feedback loop resulting in increased production of both Ang II and aldosterone.40–42 Furthermore, Rickard et al. demonstrated macrophage-specific KO of mineralocorticoid receptors protected against DoCa-induced cardiac fibrosis and hypertension.43 However, question remains of how is proinflammatory transcriptional factor NF-κB activated in macrophage in response to Ang II.

Interestingly, CARD9 is selectively involved in the activation of NF-κB and MAPKs, which is required for the production of proinflammatory cytokines in innate immune responses to intracellular pathogens.11,44–46 CARD9 signals allow the Toll-like receptor and Nod2 pathways to induce MAPK activation (including p38 and JNK1/2) and increased levels of phosphorylated NF-κB/p65, p38, and JNK1/2 in macrophages from WT mice. In contrast, macrophages from CARD9−/− mice showed no significant activation of NF-κB, p38, JNK1/2 with Ang II treatment (Figure 4b). Thus, CARD9 is involved in Ang II–mediated regulation of NF-κB and MAPKs in the heart.

**DISCUSSION**

Although Ang II has powerful proinflammatory effects on cardiac fibrosis and inflammation, the precise molecular mechanisms for these effects are not fully understood.24–28 In the present study, we found that Ang II significantly stimulated the infiltration of CARD9+ macrophages into hearts. Importantly, CARD9−/− prevented Ang II–induced inflammation and cardiac fibrosis. These effects were associated with reduced activation of the NF-κB/MAPK signaling pathway, expression of proinflammatory cytokines and accumulation of α-SMA+ myofibroblasts with Ang II infusion. Thus, CARD9 is important in hypertensive cardiac remodeling induced by Ang II infusion.

Cardiac fibrosis and inflammation are the major events of Ang II–induced myocardial remodeling. CARD9 is a caspase recruitment–domain–containing signaling protein expressed in various tissues.10,11 It is closely associated with several inflammatory diseases, including tuberculosis, inflammatory bowel disease, tuberculosis, and ankylosing spondylitis.13,29,30 In CARD9−/− mice, stimulation of dendritic cells caused a marked decrease in the production of IL-2, -6, and -10, and TNF-α and decreased numbers of Th17 cells.31–33 Humans with CARD9 mutation show defects in inflammation responses.34 Given the important role of CARD9 in inflammation, we investigated the role of CARD9 in cardiac inflammation and fibrosis after Ang II infusion. We found infiltrated macrophages expressing CARD9 in response to Ang II infusion. The critical role of CARD9 was demonstrated by Ang II–induced macrophage infiltration, and the expression of TGF-β, collagen I, α-SMA, IL-1β, and CTGF was significantly inhibited in CARD9−/− mice with Ang II infusion (Figures 2 and 3).

Myofibroblast formation is controlled by a number of growth factors, cytokines, and mechanical stimuli.35 In the present study, the number of α-SMA+ myofibroblasts in myocardial tissues of CARD9−/− mice was significantly lower than that of WT mice after Ang II infusion (Figure 3). Moreover, the expression of collagen I and TGF-β was markedly decreased in CARD9−/− mice (Figure 3). Therefore, CARD9 deficiency inhibits cardiac fibrosis by inhibiting myofibroblast formation.

Increasing evidence has demonstrated that Ang II, via its type 1 receptor, activates a number of signaling pathways, including reactive oxygen species, MAPKs, receptor- or nonreceptor-associated tyrosine kinases, and transcriptional factors such as NF-κB, Ets-1, and early growth response 1 to regulate cardiac hypertrophy, inflammation, and fibrosis.36 Among these, NF-κB and MAPK signaling pathways play pivotal roles in regulating the inflammatory, immune, and apoptotic responses in mammals.37 Ang II, via AT1R activation, also increases production of aldosterone which is a steroid hormone with mineralocorticoid activity. Beyond its effects on renal sodium reabsorption, aldosterone exerts effects on the kidney, blood vessels, and the heart, and plays an important role in renal and cardiovascular injury, including inflammation, tissue remodeling and fibrosis, has been demonstrated in various animal models of hypertension.38,39 The aldosterone increases tissue angiotensin-converting enzyme activity and upregulates AT1, indicating a vicious forward feedback loop resulting in increased production of both Ang II and aldosterone.40–42 Furthermore, Rickard et al. demonstrated macrophage-specific KO of mineralocorticoid receptors protected against DoCa-induced cardiac fibrosis and hypertension.43 However, question remains of how is proinflammatory transcriptional factor NF-κB activated in macrophage in response to Ang II.

Interestingly, CARD9 is selectively involved in the activation of NF-κB and MAPKs, which is required for the production of proinflammatory cytokines in innate immune responses to intracellular pathogens.11,44–46 CARD9 signals allow the Toll-like receptor and Nod2 pathways to induce MAPK activation (including p38 and JNK1/2) and increased levels of phosphorylated NF-κB/p65, p38, and JNK1/2 in macrophages from WT mice. In contrast, macrophages from CARD9−/− mice showed no significant activation of NF-κB, p38, JNK1/2 with Ang II treatment (Figure 4b). Thus, CARD9 is involved in Ang II–mediated regulation of NF-κB and MAPKs in the heart.
CARD9 Regulates Inflammation and Cardiac Fibrosis

In conclusion, we revealed an important role of CARD9 in Ang II infusion–induced cardiac remodeling. CARD9 deficiency inhibited inflammatory cells infiltration, expression of proinflammatory cytokines, accumulation of myofibroblasts, and cardiac fibrosis with Ang II treatment. These effects might be a result of inhibiting the activation of NF-κB and MAPKs.

Acknowledgments: This study was supported by grants from Chinese Ministry of Science and Technology (2009CB522205) and National Science Foundation of China (30888004). Dr Xin is a visiting professor from Department of Molecular and Cellular Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, TX. Dr. J.C. is a visiting professor from Division of Nephrology, Baylor College of Medicine, Houston, TX.

Disclosure: The authors declared no conflict of interest.

1. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91:988–998.
2. Diez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich) 2007; 9:546–550.
3. Ferrari CM, Stavrin WBN. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121–128.
4. Bhardwaj R, Fujiwara K, Leshou S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007; 117:568–575.
5. Haudek SB, Cheng J, Du J, Wang Y, Hermosillo-Rodriguez J, Trial J, Taftet GE, Entman ML. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J Mol Cell Cardiol 2010, 49:499–507.
6. Haudek SB, Xia Y, Huebener P, Lee JM, Carlson S, Crawford JR, Pilling D, Gomer RH, Trial J, Frangogiannis NG, Entman ML. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci USA 2006, 103:18284–18289.
7. Zhang L, Ma Y, Zhang J, Cheng J, Du J. A new cellular signaling mechanism for angiotensin II activation of NF-κappab. An IκappaB-independent, RSK-mediated phosphorylation of p65. Arterioscler Thromb Vasc Biol 2005; 25:1148–1153.
8. Ma Y, Zhang L, Peng Y, Cheng J, Tannia S, Zhang J, Delafontaine P, Du J. Angiotensin II stimulates transcription of insulin-like growth factor I receptor in vascular smooth muscle cells: role of nuclear factor-kappaB. Endocrinology 2006; 147:1256–1263.
9. Zhang L, Cheng J, Ma Y, Thomas W, Zhang J, Du J. Dual pathways for nuclear factor kappaB activation by angiotensin II in vascular smooth muscle: phosphorylation of p65 by IκappaB kinase and ribosomal kinase. Circ Res 2005; 97:975–982.
10. Berton J, Guo Y, Wang H, Sinhravisam GL, Jacobson MD, Foyer JL, Memurn S, Du J, Dyer MJ, Dyson MJ, Rice SA, Lawson KE, Stiftefre PS, Allemman ES. CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-κappab. J Biol Chem 2000; 275:41082–41086.
11. Hsu YM, Zhang Y, You Y, Wang D, Li H, Duramad O, Qin XF, Dong C, Lin X. The cytokine-induced nuclear factor-kappaB (NF-κB) activator CARD9 is a candidate gene.
12. Hsu YM, Zhang Y, You Y, Wang D, Li H, Duramad O, Qin XF, Dong C, Lin X. The cytokine-induced nuclear factor-kappaB (NF-κB) activator CARD9 is a candidate gene.
13. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cellular events: role of aldosterone. J Am Soc Nephrol 2005, 16:371–383.
14. Zhao Q, Ishibashi M, Haara K, Tan C, Takehita A, Egashira K. Essential role of vascular endothelial growth factor in angiotensin-II-induced vascular inflammation and remodeling. Hypertension 2004; 44:264–270.
15. Zhao W, Ahokas RA, Weber KT, Sun Y. ANG-II-induced cardiac molecular and cellular events: role of aldosterone. Am J Physiol Heart Circ Physiol 2006; 291:H1336–H143.
16. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schutz G, Lumeng CN, Mortensen RM. Myeloid melanocorticotoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 2010; 120:3350–3364.
17. Huang XR, Chuang AC, Yang F, Yue W, Deng C, Lau CP, Tse HF, Lan HY. Smad3 mediates cardiac inflammation and fibrosis in angiotensin-II-induced hypertensive cardiac remodeling. Hypertension 2010; 55:1165–1171.
18. McAlister-Lucas LM, Ruland J, Liu S, Kim J, Lin X, Gu S, Kim DS, Kuffa P, Kohrt D, Mak TW, Nuthe G, Lucas PC, Carmack BE. Bcl10/MALT1-dependent NF-κappab activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci USA 2007; 104:139–144.
19. de Vries HS, Plantinga TS, van Krieken JH, Stienstra R, van Bodegraven AA, Feesten EA, Weersma RK, Cruysius JB, Linksens RK, Joosten LA, Netea MG, de Jong DJ. Genetic association analysis of the functional c.7147T>G polymorphism and mucosal expression of defensin-1 in inflammatory bowel disease. PLoS ONE 2009; 4:e7678.
20. Pointon JJ, Harvey D, Karadener T, Appleton LH, Farrar C, Stone MA, Sturrock RD, Brown MA, Wordsworth BP. ELucidating the chromosome 9 association with AS, CARD9 is a candidate gene. Genes Immun 2010; 11:490–496.
21. Sajjo S, Ikeda S, Yamabe K, Katsuki S, Ishigame H, Akutsu A, Fukigado N, Kusaka T, Kubo S, Chig Sh, Komatsu R, Miura N, Adachi Y, Ohno N, Shibuya K, Ratafia MJ, Douglas JN, Kawakami M, Yamashita S, Saito T, Akita S, Ishikawa Y. Deficit-2 recognition of α-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity 2010; 32:681–691.
22. Robinson MJ, Osofo C, Rosas M, Freitas RP, Schweighofer E, Gross O, Verbeek JS, Ruland J, Tyubulevich V, Brown GD, Moita LF, Taylor PR, Reis e Sousa C. Deficit-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J Exp Med 2009; 206:2037–2051.
23. Milner JD, Sandler NG, Dosek DC, TH17 cells, Job’s syndrome and HIV: opportunities for viral and bacterial infections. Curr Opin HIV AIDS 2010; 5:179–183.
24. Glöcker EG, Hennings A, Nabavi M, Schäffer AA, Woelner C, Salzer U, Pfeifer D, Veelken H, Wutzat K, Tahami F, Jamil S, Manguasit A, Rezaei N, Arzumugam AR, Plebani A, Hannenschläger N, Gross O, Ruland J, Grimbacher B. A homologous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009; 361:1721–1735.
25. Punter T, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009; 123:255–278.
26. Mehta PK, Grimminger FK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292:C282–C297.
27. Bruckner AL. Incontinerea pigmenta: a window to the role of NF-κappab. Faseed 2004; 18:116–124.
28. Young M, Fullerton M, Dilley R, Funder J. Melanocorticotoids, hypertension, and cardiac fibrosis. J Clin Invest 1994; 93:2578–2583.
29. Blasi ER, Rocha R, Rudolph AE, Weersma RK, Crusius JB, Lin N, Sasaki T, Ichikawa T, Tomiyama J, Fujikado N, Kusaka T, Takeda S, Nozawa Y, Takahashi A. Essential role of TGF-β1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol 2005, 16:371–383.
30. Stier CT Jr, Koenig S, Lee DY, Chawla M, Frishman WH. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Insprava). Heart Dis 2003; 5:102–118.
41. Schiffrin EL, Gutkowska J, Genest J. Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am J Physiol 1984; 246:H608–H614.

42. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, Mizuno Y, Nakayama M, Shimasaki Y, Ito T, Nakamura S, Kuwahara K, Saito Y, Nakao K, Oga H. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001; 104:137–139.

43. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009; 54:537–543.

44. Han J, Ulevitch RJ. Limiting inflammatory responses during activation of innate immunity. Nat Immunol 2005; 6:1198–1205.

45. Ashwell JD. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol 2006; 6:532–540.

46. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002; 20:55–72.

This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/